Nutriband (NTRB) Expected to Announce Quarterly Earnings on Tuesday

Nutriband (NASDAQ:NTRB) is projected to announce its results before the market opens on Tuesday, December 2nd. Analysts expect the company to announce earnings of ($2.13) per share for the quarter.

Nutriband (NASDAQ:NTRB) last announced its quarterly earnings data on Tuesday, September 9th. The company reported ($2.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.95). Nutriband had a negative return on equity of 85.40% and a negative net margin of 398.29%.The business had revenue of $0.62 million for the quarter, compared to analyst estimates of $0.71 million. On average, analysts expect Nutriband to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nutriband Trading Down 2.1%

NASDAQ:NTRB opened at $4.68 on Tuesday. The stock has a market cap of $56.32 million, a PE ratio of -1.63 and a beta of 1.54. Nutriband has a fifty-two week low of $3.72 and a fifty-two week high of $11.78. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.78 and a quick ratio of 4.70. The stock’s 50-day moving average is $6.76 and its two-hundred day moving average is $7.01.

Institutional Trading of Nutriband

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. grew its holdings in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 202,738 shares of the company’s stock after purchasing an additional 3,111 shares during the quarter. Vanguard Group Inc. owned about 1.68% of Nutriband worth $1,429,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 19.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on NTRB. Zacks Research raised shares of Nutriband from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nutriband in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Nutriband from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nutriband currently has an average rating of “Hold” and an average price target of $13.00.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.